AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2011-08-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT00829127
Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066
Phase 1
Completed
- Conditions
- Pain
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2009-02-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT00829088
- Locations
- 🇬🇧
Research Site, Cheshire, United Kingdom
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00826358
- Locations
- 🇺🇸
Site Reference ID/Investigator# 13441, Orlando, Florida, United States
Ciclesonide for the Treatment of Airway Hyperresponsiveness
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT00826969
- Locations
- 🇨🇭
Nycomed, Basel, Switzerland
Study of Mental Care in Spain
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2009-09-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 76
- Registration Number
- NCT00824031
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2)
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2009-07-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00824057
- Locations
- 🇬🇧
Research Site, London, United Kingdom
To Evaluate 24-hr Glucose After OD vs BD AZD1656
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2009-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00819884
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Investigation Into the Correlation of Plasma Hs-CRP Concentrations and Cardiovascular Risk in Korean Population
Completed
- Conditions
- hsCRP
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1700
- Registration Number
- NCT00819273
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT00819221
- Locations
- 🇨🇭
Research Site, Chur, Switzerland
A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components
Phase 4
Completed
- Conditions
- Primary Hypertension
- Interventions
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2009-09-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 402
- Registration Number
- NCT00819104
- Locations
- 🇮🇳
Research Site, Delhi, India
© Copyright 2025. All Rights Reserved by MedPath